Plerixafor for autologous CD34+ cell mobilization

Huda Salman, Hillard M. Lazarus

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34+ cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis by the CXCR4 antagonist, plerixafor, has been demonstrated in Phase II and Phase III trials to improve mobilization when used in conjunction with granulocyte colony-stimulating factor (G-CSF). This approach is safe with few adverse events and produces significantly greater numbers of CD34 + cells when compared to G-CSF alone. New plerixafor initiatives include use in volunteer donors for allogeneic hematopoietic cell transplant and in other disease targets.

Original languageEnglish (US)
Pages (from-to)23-29
Number of pages7
JournalCore Evidence
Volume6
DOIs
StatePublished - Feb 7 2011

Fingerprint

Granulocyte Colony-Stimulating Factor
Cell Count
Autologous Transplantation
Chemokine Receptors
Hematologic Neoplasms
Hematopoietic Stem Cells
Volunteers
Tissue Donors
Ligands
Transplants
Drug Therapy
JM 3100
Therapeutics

Keywords

  • Autologous hematopoietic cell transplant
  • CD34
  • Granulocyte colony-stimulating factor (G-CSF)
  • Lymphoma
  • Myeloma
  • Plerixafor

ASJC Scopus subject areas

  • Reviews and References, Medical
  • Pharmacology

Cite this

Plerixafor for autologous CD34+ cell mobilization. / Salman, Huda; Lazarus, Hillard M.

In: Core Evidence, Vol. 6, 07.02.2011, p. 23-29.

Research output: Contribution to journalReview article

Salman, Huda ; Lazarus, Hillard M. / Plerixafor for autologous CD34+ cell mobilization. In: Core Evidence. 2011 ; Vol. 6. pp. 23-29.
@article{8f8be3e72937471da119888d79ca426a,
title = "Plerixafor for autologous CD34+ cell mobilization",
abstract = "High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34+ cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis by the CXCR4 antagonist, plerixafor, has been demonstrated in Phase II and Phase III trials to improve mobilization when used in conjunction with granulocyte colony-stimulating factor (G-CSF). This approach is safe with few adverse events and produces significantly greater numbers of CD34 + cells when compared to G-CSF alone. New plerixafor initiatives include use in volunteer donors for allogeneic hematopoietic cell transplant and in other disease targets.",
keywords = "Autologous hematopoietic cell transplant, CD34, Granulocyte colony-stimulating factor (G-CSF), Lymphoma, Myeloma, Plerixafor",
author = "Huda Salman and Lazarus, {Hillard M.}",
year = "2011",
month = "2",
day = "7",
doi = "10.2147/CE.S7801",
language = "English (US)",
volume = "6",
pages = "23--29",
journal = "Core Evidence",
issn = "1555-1741",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Plerixafor for autologous CD34+ cell mobilization

AU - Salman, Huda

AU - Lazarus, Hillard M.

PY - 2011/2/7

Y1 - 2011/2/7

N2 - High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34+ cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis by the CXCR4 antagonist, plerixafor, has been demonstrated in Phase II and Phase III trials to improve mobilization when used in conjunction with granulocyte colony-stimulating factor (G-CSF). This approach is safe with few adverse events and produces significantly greater numbers of CD34 + cells when compared to G-CSF alone. New plerixafor initiatives include use in volunteer donors for allogeneic hematopoietic cell transplant and in other disease targets.

AB - High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34+ cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis by the CXCR4 antagonist, plerixafor, has been demonstrated in Phase II and Phase III trials to improve mobilization when used in conjunction with granulocyte colony-stimulating factor (G-CSF). This approach is safe with few adverse events and produces significantly greater numbers of CD34 + cells when compared to G-CSF alone. New plerixafor initiatives include use in volunteer donors for allogeneic hematopoietic cell transplant and in other disease targets.

KW - Autologous hematopoietic cell transplant

KW - CD34

KW - Granulocyte colony-stimulating factor (G-CSF)

KW - Lymphoma

KW - Myeloma

KW - Plerixafor

UR - http://www.scopus.com/inward/record.url?scp=84856287313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856287313&partnerID=8YFLogxK

U2 - 10.2147/CE.S7801

DO - 10.2147/CE.S7801

M3 - Review article

C2 - 21468240

AN - SCOPUS:84856287313

VL - 6

SP - 23

EP - 29

JO - Core Evidence

JF - Core Evidence

SN - 1555-1741

ER -